Literature DB >> 28017435

Informing vaccine decision-making: A strategic multi-attribute ranking tool for vaccines-SMART Vaccines 2.0.

Stacey Knobler1, Karin Bok2, Bruce Gellin2.   

Abstract

SMART Vaccines 2.0 software is being developed to support decision-making among multiple stakeholders in the process of prioritizing investments to optimize the outcomes of vaccine development and deployment. Vaccines and associated vaccination programs are one of the most successful and effective public health interventions to prevent communicable diseases and vaccine researchers are continually working towards expanding targets for communicable and non-communicable diseases through preventive and therapeutic modes. A growing body of evidence on emerging vaccine technologies, trends in disease burden, costs associated with vaccine development and deployment, and benefits derived from disease prevention through vaccination and a range of other factors can inform decision-making and investment in new and improved vaccines and targeted utilization of already existing vaccines. Recognizing that an array of inputs influences these decisions, the strategic multi-attribute ranking method for vaccines (SMART Vaccines 2.0) is in development as a web-based tool-modified from a U.S. Institute of Medicine Committee effort (IOM, 2015)-to highlight data needs and create transparency to facilitate dialogue and information-sharing among decision-makers and to optimize the investment of resources leading to improved health outcomes. Current development efforts of the SMART Vaccines 2.0 framework seek to generate a weighted recommendation on vaccine development or vaccination priorities based on population, disease, economic, and vaccine-specific data in combination with individual preference and weights of user-selected attributes incorporating valuations of health, economics, demographics, public concern, scientific and business, programmatic, and political considerations. Further development of the design and utility of the tool is being carried out by the National Vaccine Program Office of the Department of Health and Human Services and the Fogarty International Center of the National Institutes of Health. We aim to demonstrate the utility of SMART Vaccines 2.0 through the engagement of a community of relevant stakeholders and to identify a limited number of pilot projects to determine explicitly defined attribute preferences and the related data and model requirements that are responsive to user needs and able to improve the use of evidence for vaccine-related decision-making and consequential priorities of vaccination options.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Global health; Public health; Vaccine; Vaccine decision making

Mesh:

Substances:

Year:  2016        PMID: 28017435     DOI: 10.1016/j.vaccine.2016.10.086

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

1.  Adjuvanted influenza vaccine for the Italian elderly in the 2018/19 season: an updated health technology assessment.

Authors:  Chiara de Waure; Sara Boccalini; Paolo Bonanni; Daniela Amicizia; Andrea Poscia; Angela Bechini; Marco Barbieri; Stefano Capri; Maria Lucia Specchia; Maria Luisa Di Pietro; Lucia Arata; Pasquale Cacciatore; Doanatella Panatto; Roberto Gasparini
Journal:  Eur J Public Health       Date:  2019-10-01       Impact factor: 3.367

Review 2.  SMART Vaccines 2.0 decision-support platform: a tool to facilitate and promote priority setting for sustainable vaccination in resource-limited settings.

Authors:  Benjamin J J McCormick; Peter Waiswa; Celia Nalwadda; Nelson K Sewankambo; Stacey L Knobler
Journal:  BMJ Glob Health       Date:  2020-11

3.  Prioritization of Vaccines for Inclusion into China's Expanded Program on Immunization: Evidence from Experts' Knowledge and Opinions.

Authors:  Chao Ma; Junhong Li; Nan Wang; Yamin Wang; Yudan Song; Xiang Zeng; Canjun Zheng; Zhijie An; Lance Rodewald; Zundong Yin
Journal:  Vaccines (Basel)       Date:  2022-06-24

4.  Pathway towards an ideal and sustainable framework agreement for the public procurement of vaccines in Spain: a multi-criteria decision analysis.

Authors:  N Zozaya González; B Alcalá Revilla; P Arrazola Martínez; J R Chávarri Bravo; I Cuesta Esteve; A J García Rojas; F Martinón-Torres; E Redondo Margüello; A Rivero Cuadrado; S Tamames Gómez; J Villaseca Carmena; A Hidalgo-Vega
Journal:  Hum Vaccin Immunother       Date:  2020-04-03       Impact factor: 3.452

5.  Value Frameworks for Vaccines: Which Dimensions Are Most Relevant?

Authors:  Jeroen Luyten; Roselinde Kessels; Corinne Vandermeulen; Philippe Beutels
Journal:  Vaccines (Basel)       Date:  2020-10-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.